|
1
|
de Lope CR, Tremosini S, Forner A, Reig M
and Bruix J: Management of HCC. J Hepatol. 56(Suppl 1): S75–S87.
2012.
|
|
2
|
Livraghi T, Mäkisalo H and Line PD:
Treatment options in hepatocellular carcinoma today. Scand J Surg.
100:22–29. 2011.PubMed/NCBI
|
|
3
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR,
Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici
M, Voliotis D and Bruix J; SHARP Investigators Study Group.
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abou-Alfa GK, Schwartz L, Ricci S, Amadori
D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz
B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib
in patients with advanced hepatocellular carcinoma. J Clin Oncol.
24:4293–4300. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J,
Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z:
Efficacy and safety of sorafenib in patients in the Asia-Pacific
region with advanced hepatocellular carcinoma: a phase III
randomised, double-blind, placebo-controlled trial. Lancet Oncol.
10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wigg AJ, Palumbo K and Wigg DR:
Radiotherapy for hepatocellular carcinoma: systematic review of
radiobiology and modeling projections indicate reconsideration of
its use. J Gastroenterol Hepatol. 25:664–671. 2010. View Article : Google Scholar
|
|
8
|
Mazzaferro V, Sposito C, Bhoori S, Romito
R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita
R, Civelli E, Bombardieri E, Camerini T and Spreafico C: Yttrium-90
radioembolization for intermediate-advanced hepatocellular
carcinoma: a phase 2 study. Hepatology. 57:1826–1837. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogl TJ, Lammer J, Lencioni R, Malagari K,
Watkinson A, Pilleul F, Denys A and Lee C: Liver, gastrointestinal,
and cardiac toxicity in intermediate hepatocellular carcinoma
treated with PRECISION TACE with drug-eluting beads: results from
the PRECISION V randomized trial. AJR Am J Roentgenol.
197:W562–W570. 2011. View Article : Google Scholar
|
|
10
|
Ueshima K, Kudo M, Takita M, Nagai T,
Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara
S, Minami Y and Chung H: Hepatic arterial infusion chemotherapy
using low-dose 5-fluorouracil and cisplatin for advanced
hepatocellular carcinoma. Oncology. 78(Suppl 1): 148–153. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takayasu K, Arii S, Ikai I, Kudo M,
Matsuyama Y, Kojiro M and Makuuchi M; Liver Cancer Study Group of
Japan. Overall survival after transarterial lipiodol infusion
chemotherapy with or without embolization for unresectable
hepatocellular carcinoma: propensity score analysis. AJR Am J
Roentgenol. 194:830–837. 2010. View Article : Google Scholar
|
|
12
|
Takayasu K, Arii S, Ikai I, Omata M, Okita
K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M and Makuuchi M:
Prospective cohort study of transarterial chemoembolization for
unresectable hepatocellular carcinoma in 8510 patients.
Gastroenterology. 131:461–469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J and
Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or
chemoembolisation versus symptomatic treatment in patients with
unresectable hepatocellular carcinoma: a randomised controlled
trial. Lancet. 359:1734–1739. 2002. View Article : Google Scholar
|
|
14
|
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM,
Poon RT, Fan ST and Wong J: Randomized controlled trial of
transarterial lipiodol chemoembolization for unresectable
hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cammà C, Schepis F, Orlando A, Albanese M,
Shahied L, Trevisani F, Andreone P, Craxì A and Cottone M:
Transarterial chemoembolization for unresectable hepatocellular
carcinoma: meta-analysis of randomized controlled trials.
Radiology. 224:47–54. 2002.PubMed/NCBI
|
|
16
|
Bruix J and Sherman M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
|
17
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishikawa H, Osaki Y, Kita R and Kimura T:
Hepatic arterial infusion chemotherapy for advanced hepatocellular
carcinoma in Japan. Cancers. 4:165–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishikawa H, Osaki Y, Kita R, Kimura T,
Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S,
Hatamaru K, Saito S and Nasu A: Transcatheter arterial infusion
chemotherapy prior to radiofrequency thermal ablation for single
hepatocellular carcinoma reduces the risk of intrahepatic distant
recurrence. Int J Oncol. 41:903–909. 2012.
|
|
20
|
Nishikawa H, Arimoto A, Wakasa T, Kita R,
Kimura T and Osaki Y: Effect of transcatheter arterial
chemoembolization prior to surgical resection for hepatocellular
carcinoma. Int J Oncol. 42:151–160. 2013.PubMed/NCBI
|
|
21
|
Intra-arterial administration of
epirubicin in the treatment of nonresectable hepatocellular
carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma.
Cancer Chemother Pharmacol. 19:183–189. 1987.PubMed/NCBI
|
|
22
|
Nishikawa H, Inuzuka T, Takeda H, Nakajima
J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita
R, Kimura T and Osaki Y: Percutaneous radiofrequency ablation
therapy for hepatocellular carcinoma: a proposed new grading system
for the ablative margin and prediction of local tumor progression
and its validation. J Gastroenterol. 46:1418–1426. 2011. View Article : Google Scholar
|
|
23
|
Hayashi M, Matsui O, Ueda K, Kawamori Y,
Gabata T and Kadoya M: Progression to hypervascular hepatocellular
carcinoma: correlation with intranodular blood supply evaluated
with CT during intraarterial injection of contrast material.
Radiology. 225:143–149. 2002. View Article : Google Scholar
|
|
24
|
Satake M, Uchida H, Arai Y, Anai H,
Sakaguchi H, Nagata T, Yamane T, Kichikawa K, Osaki Y, Okazaki M,
Higashihara H, Nakamura H, Osuga K, Nakao N and Hirota S:
Transcatheter arterial chemoembolization (TACE) with lipiodol to
treat hepatocellular carcinoma: survey results from the TACE study
group of Japan. Cardiovasc Intervent Radiol. 31:756–761. 2008.
View Article : Google Scholar
|
|
25
|
Minami Y and Kudo M: Therapeutic response
assessment of transcatheter arterial chemoembolization for
hepatocellular carcinoma: ultrasonography, CT and MR imaging.
Oncology. 84(Suppl 1): 58–63. 2013. View Article : Google Scholar
|
|
26
|
Kudo M, Kubo S, Takayasu K, Sakamoto M,
Tanaka M, Ikai I, Furuse J, Nakamura K and Makuuchi M; Liver Cancer
Study Group of Japan (Committee for Response Evaluation Criteria in
Cancer of the Liver, Liver Cancer Study Group of Japan). Hepatol
Res. 40:686–692. 2010. View Article : Google Scholar
|
|
27
|
Imaeda T, Yamawaki Y, Seki M, Goto H,
Iinuma G, Kanematsu M, Mochizuki R, Doi H, Saji S and Shimokawa K:
Lipiodol retention and massive necrosis after
lipiodol-chemoembolization of hepatocellular carcinoma: correlation
between computed tomography and histopathology. Cardiovasc
Intervent Radiol. 16:209–213. 1993. View Article : Google Scholar
|
|
28
|
Jun CH, Ki HS, Lee HK, Park KJ, Park SY,
Cho SB, Park CH, Joo YE, Kim HS, Choi SK and Rew JS: Clinical
significance and risk factors of postembolization fever in patients
with hepatocellular carcinoma. World J Gastroenterol. 19:284–289.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okusaka T, Kasugai H, Shioyama Y, Tanaka
K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K,
Yamamoto S, Hinotsu S and Sato T: Transarterial chemotherapy alone
versus transarterial chemoembolization for hepatocellular
carcinoma: a randomized phase III trial. J Hepatol. 51:1030–1036.
2009. View Article : Google Scholar
|
|
30
|
Ikeda M, Maeda S, Shibata J, Muta R,
Ashihara H, Tanaka M, Fujiyama S and Tomita K: Transcatheter
arterial chemotherapy with and without embolization in patients
with hepatocellular carcinoma. Oncology. 66:24–31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raoul JL, Sangro B, Forner A, Mazzaferro
V, Piscaglia F, Bolondi L and Lencioni R: Evolving strategies for
the management of intermediate-stage hepatocellular carcinoma:
available evidence and expert opinion on the use of transarterial
chemoembolization. Cancer Treat Rev. 37:212–220. 2011. View Article : Google Scholar
|
|
32
|
Ishikawa T: Future perspectives on the
treatment of hepatocellular carcinoma with cisplatin. World J
Hepatol. 1:8–16. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nishikawa H and Osaki Y: Clinical
significance of therapy using branched-chain amino acid granules in
patients with liver cirrhosis and hepatocellular carcinoma. Hepatol
Res. Jul 2–2013. View Article : Google Scholar : (Epub ahead of
print).
|
|
34
|
Ikeda M, Mitsunaga S, Shimizu S, Ohno I,
Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H,
Satake M, Arai Y and Okusaka T: Efficacy of sorafenib in patients
with hepatocellular carcinoma refractory to transcatheter arterial
chemoembolization. J Gastroenterol. Jun 23–2013.(Epub ahead of
print).
|
|
35
|
Poon RT, Fan ST, Lo CM, Liu CL, Ngan H, Ng
IO and Wong J: Hepatocellular carcinoma in the elderly: results of
surgical and nonsurgical management. Am J Gastroenterol.
94:2460–2466. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yau T, Yao TJ, Chan P, Epstein RJ, Ng KK,
Chok SH, Cheung TT, Fan ST and Poon RT: The outcomes of elderly
patients with hepatocellular carcinoma treated with transarterial
chemoembolization. Cancer. 115:5507–5515. 2009. View Article : Google Scholar : PubMed/NCBI
|
